RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Syndax Pharmaceuticals Stock

Syndax Pharmaceuticals P/S 2024

Syndax Pharmaceuticals P/S

10.82

Ticker

SNDX

ISIN

US87164F1057

WKN

A2AFL6

As of Dec 20, 2024, Syndax Pharmaceuticals's P/S ratio stood at 10.82, a 0% change from the 0 P/S ratio recorded in the previous year.

The Syndax Pharmaceuticals P/S history

Syndax Pharmaceuticals Aktienanalyse

What does Syndax Pharmaceuticals do?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Syndax Pharmaceuticals's P/S Ratio

Syndax Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Syndax Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Syndax Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Syndax Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Syndax Pharmaceuticals stock

What is the price-to-earnings ratio of Syndax Pharmaceuticals?

The price-earnings ratio of Syndax Pharmaceuticals is currently 10.82.

How has the price-earnings ratio of Syndax Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Syndax Pharmaceuticals has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Syndax Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Syndax Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Syndax Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Syndax Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Syndax Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Syndax Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Syndax Pharmaceuticals?

Some factors that influence the price-earnings ratio of Syndax Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Syndax Pharmaceuticals pay?

Over the past 12 months, Syndax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Syndax Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Syndax Pharmaceuticals?

The current dividend yield of Syndax Pharmaceuticals is .

When does Syndax Pharmaceuticals pay dividends?

Syndax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Syndax Pharmaceuticals?

Syndax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Syndax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Syndax Pharmaceuticals located?

Syndax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Syndax Pharmaceuticals from 12/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/20/2024.

When did Syndax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/20/2024.

What was the dividend of Syndax Pharmaceuticals in the year 2023?

In the year 2023, Syndax Pharmaceuticals distributed 0 USD as dividends.

In which currency does Syndax Pharmaceuticals pay out the dividend?

The dividends of Syndax Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Syndax Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Syndax Pharmaceuticals

Our stock analysis for Syndax Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Syndax Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.